Education
About Us
Working with TipRanks
Follow Us
GT Biopharma (GTBP)
NASDAQ:GTBP
Total Valuation
GT Biopharma has a market cap or net worth of $5.66M. The enterprise value is $2.77M.
Market Cap$5.66M
Enterprise Value$2.77M
Share Statistics
GT Biopharma has 2.54M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2.54M
Owened by Insiders
Owened by Instutions0.07%
Financial Efficiency
GT Biopharma’s return on equity (ROE) is 7.88 and return on invested capital (ROIC) is 860.12%.
Return on Equity (ROE)788.14%
Return on Assets (ROA)-311.01%
Return on Invested Capital (ROIC)860.12%
Return on Capital Employed (ROCE)860.12%
Revenue Per Employee$0
Profits Per Employee-$13,162,000
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of GT Biopharma is -0.44. GT Biopharma’s PEG ratio is -0.02.
PE Ratio-0.44
PS Ratio0.00
PB Ratio-3.47
Price to Fair Value-3.47
Price to FCF-0.45
Price to Operating Cash Flow-0.45
PEG Ratio-0.02
Income Statement
In the last 12 months, GT Biopharma had revenue of $0.00 and earned -$13.16M in profits. Earnings per share was -$7.33.
Revenue$0.00
Gross Profit$0.00
Operating Income-$14.36M
Pretax Income-$13.16M
Net Income-$13.16M
EBITDA-10.07M
Earnings Per Share (EPS)-7.33
Cash Flow
In the last 12 months, operating cash flow was -$12.90M and capital expenditures $0.00, giving a free cash flow of -$12.90M billion.
Operating Cash Flow-$12.90M
Free Cash Flow-$12.90M
Free Cash Flow per Share-$5.09
Dividends & Yields
GT Biopharma pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-222.98%
Earnings Yield-227.44%
Stock Price Statistics
Beta1.02
52-Week Price Change-41.32%
50-Day Moving Average2.30
200-Day Moving Average2.48
Relative Strength Index (RSI)50.43
Average Volume (3m)33.26K
Important Dates
GT Biopharma upcoming earnings date is May 19, 2025, Before Open.
Last Earnings DateFeb 21, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
GT Biopharma as a current ratio of 0.72, with Debt / Equity ratio of 0.00
Current Ratio0.72
Quick Ratio0.72
Debt to Market Cap0.00
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, GT Biopharma has paid -$3.09M in taxes.
Income Tax-$3.09M
Effective Tax Rate0.00%
Enterprise Valuation
GT Biopharma EV to EBITDA ratio is -0.13, with an EV/FCF ratio of -0.14.
EV to Sales0.00
EV to EBITDA-0.13
EV to Free Cash Flow-0.14
EV to Operating Cash Flow-0.14
Balance Sheet
GT Biopharma has $3.95M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$3.95M billion.
Cash & Marketable Securities$3.95M
Total Debt$0.00
Net Cash-$3.95M
Net Cash Per Share-$1.56
Tangible Book Value Per Share-$0.88
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for GT Biopharma is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside393.27%
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast-26.02%